This targeted guideline update clarifies when to favor hormonal therapy and spironolactone over prolonged antibiotics in female acne patients, with pregnancy-specific and contraceptive counseling implications for pharmacists.
isotretinoinspironolactonecombined oral contraceptivesdoxycyclinelymecyclinebenzoyl peroxidetrifaroteneclascoteroneacne vulgarisantimicrobial stewardshiphormonal therapyclinical practice guidelinewomen's healthWomen's Health
Background Information
Revamped acne treatment guidelines emphasize isotretinoin and hormonal therapies.
Guidelines update best practices for treating acne, crucial for patient outcomes, especially in women with specific hormonal considerations. Recommendations updated on isotretinoin, systemic antibiotics, hormonal treatments like spironolactone, and new topicals trifarotene and clascoterone. Important for selecting appropriate acne treatments, considering patient groups and safe options during pregnancy; guidelines based on robust evidence. Updated guidelines refine acne treatment strategies with clear indications and safety profiles.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Nast A, Al Wattar BH, Beylot Barry M, Brüggemann H, Bukvić Mokos Z, Caruana DM, Degitz K, Dessinioti C, Dréno B, Driessen RJB, Gollnick H, Hædersdal M, Katoulis A, Läuchli S, Lambert J, Layton AM, Micali G, Ochsendorf FR, Sathyapalan T, Stangeland KZ, Thomsen SF, Töröcsik D, Pennitz A
Citation:Nast A, Al Wattar BH, Beylot Barry M, et al. Update of the EuroGuiDerm evidence-based guideline for the treatment of acne-Short version. Journal of the European Academy of Dermatology and Venereology : JEADV. 2026;40(7):1162-1172. doi:10.1111/jdv.70331